Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2021 16:05 ET | Source: Beyond Air™

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021

Submitted first premarket approval (PMA) application in the Company’s history to FDA for LungFit® PH to treat persistent pulmonary hypertension of the newborn (PPHN); Company preparing for commercial...
May 26, 2021 07:30 ET | Source: Beyond Air™

Beyond Air® Reaches Settlement Agreement with Circassia for LungFit® PH

GARDEN CITY, N.Y., May 26, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...
May 25, 2021 07:30 ET | Source: Beyond Air™

Beyond Air® Schedules Fiscal Year 2021 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., May 25, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...
May 20, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® Strengthens Commercial Leadership Team with Appointments of Head of Sales and Head of Marketing

GARDEN CITY, N.Y., May 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...
May 13, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021

Interim analysis from the ongoing, open-label, randomized acute viral pneumonia (including COVID-19) pilot study shows 150 ppm nitric oxide (NO) administered with LungFit® PRO is well-tolerated with...
May 03, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® Appoints Peter Senior as Director of Business Development

GARDEN CITY, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...
April 14, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in May 2021

GARDEN CITY, N.Y., April 14, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
March 24, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® to Present Abstracts at the American Thoracic Society Virtual Sessions in May 2021

GARDEN CITY, N.Y., March 24, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric NO for the...
March 01, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® Announces Participation at Upcoming Virtual Investor Conferences in March 2021

GARDEN CITY, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
February 16, 2021 08:00 ET | Source: Beyond Air™

Beyond Air® Receives Grant for Up to $2.17 million from the Cystic Fibrosis Foundation to Advance the Clinical Development of Inhaled Nitric Oxide to Treat Nontuberculous Mycobacteria Pulmonary Disease

Award will help fund the development of high concentration nitric oxide (NO) for Nontuberculous Mycobacteria (NTM) pulmonary disease, which disproportionately affects cystic fibrosis (CF) patients ...